Beam Therapeutics Inc (BEAM)

08:40 AM

Will Beam Therapeutics Inc. stock benefit from interest rate changesFree Market Dynamics Reports - jammulinksnews.com

08:40 AM

05:10 AM

What makes Beam Therapeutics Inc. stock attractive to long term investorsSuperior stock selection - jammulinksnews.com

05:10 AM

01:10 AM

What analysts say about Beam Therapeutics Inc. stockFree Popular Stock Recommendations - PrintWeekIndia

01:10 AM

Jul 24, 2025

Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 24, 2025

Jul 24, 2025

Can Beam Therapeutics Inc. stock recover from recent declineFree Smart Trading Workshop - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

What institutions are buying Beam Therapeutics Inc. stock nowMarket-leading capital gains - jammulinksnews.com

Jul 24, 2025

Jul 23, 2025

Beam Therapeutics Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional

Jul 23, 2025

Jul 22, 2025

What drives Beam Therapeutics Inc. stock priceDynamic investment opportunities - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Beam Therapeutics Inc. a good long term investmentRobust financial gains - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025

Jul 21, 2025

Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN

Jul 21, 2025

Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025

Jul 14, 2025

(BEAM) Trading Report - news.stocktradersdaily.com

Jul 14, 2025

Jul 13, 2025

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN

Jul 13, 2025

Jul 08, 2025

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN

Jul 08, 2025

Jul 07, 2025

Cathie Wood’s ARK ETF bolsters Beam stock, sheds Roblox - Investing.com

Jul 07, 2025

Jul 06, 2025

Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest

Jul 06, 2025

Jul 04, 2025

Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN

Jul 04, 2025

Jul 04, 2025

Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail

Jul 04, 2025

Jul 01, 2025

H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com

Jul 01, 2025

Jun 30, 2025

Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest

Jun 30, 2025

Jun 30, 2025

Top 10 CRISPR Stocks to Buy Now - Insider Monkey

Jun 30, 2025

Jun 30, 2025

Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener

Jun 30, 2025

Jun 27, 2025

3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail

Jun 27, 2025

Jun 24, 2025

BEAM-101 shows sustained benefits as treatment for sickle cell - Sickle Cell Disease News

Jun 24, 2025

Jun 20, 2025

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha

Jun 20, 2025

Jun 19, 2025

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance

Jun 19, 2025

Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025

Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo Finance

Jun 18, 2025